Search

CN-121987695-A - Application of shinyleaf yellowhorn extract in preparation of medicines for preventing and/or treating microwave radiation injury

CN121987695ACN 121987695 ACN121987695 ACN 121987695ACN-121987695-A

Abstract

The invention provides application of shinyleaf yellowhorn extract in preparing a medicament for preventing and/or treating microwave radiation injury. The shinyleaf yellowhorn kernel extract is residues after oil extraction of shinyleaf yellowhorn kernels. Experimental results show that the shinyleaf yellowhorn kernel extract has a protective effect on microwave radiation injury, can be particularly used for improving the survival rate of nerves, cardiac muscles and germ cells after microwave radiation, reducing apoptosis, reducing ROS (reactive oxygen species), increasing MDA (MDA) content, enhancing the activities of SOD, GPX and CAT (CAT) and scavenging hydroxyl free radicals in vitro, has no toxicity on the cells, and provides a new product and thought for the development of medicines for preventing and/or treating microwave radiation injury.

Inventors

  • YAO BINWEI
  • LIU SHUCHEN
  • PENG RUIYUN
  • ZHANG JING
  • ZHANG GUANGJIE

Assignees

  • 中国人民解放军军事科学院军事医学研究院

Dates

Publication Date
20260508
Application Date
20260205

Claims (8)

  1. 1. Application of xanthoceras sorbifolia kernel extract in preparing medicine for preventing and/or treating microwave radiation injury is provided.
  2. 2. The use according to claim 1, wherein in the use the shinyleaf yellowhorn kernel extract is the residue of the shinyleaf yellowhorn kernel after oil extraction.
  3. 3. The use according to claim 2, wherein the shinyleaf yellowhorn kernel extract is prepared by a process comprising the steps of: drying shinyleaf yellowhorn kernel, pulverizing, extracting kernel oil by supercritical CO 2 , and collecting residue after oil extraction.
  4. 4. Use according to claim 3, characterized in that the supercritical CO 2 extraction temperature is 35-55 ℃ and the extraction pressure is 15-35MPa; the supercritical CO 2 extraction is carried out for a plurality of times, specifically 2 times, each time for 1-2 hours.
  5. 5. The use according to claim 3, characterized in that said method further comprises the operation of drying the obtained residue, said drying having a temperature of 40-50 ℃.
  6. 6. The use according to claim 1, wherein the microwave radiation is S-band microwave radiation, frequency 2450MHz.
  7. 7. The use according to claim 1, wherein the use is the use of shinyleaf yellowhorn kernel extract for the preparation of a medicament having any one of the following functions: 1) Improving the survival rate of nerve, cardiac muscle and germ cells after microwave radiation; 2) Reducing apoptosis of nerves, cardiac muscle and germ cells after microwave radiation; 3) Reducing the rise in ROS content of nerves, cardiac muscles and germ cells caused by microwave radiation; 4) Reducing the MDA content of nerve, cardiac muscle and germ cells caused by microwave radiation; 5) Enhancing the activity of SOD of nerve, cardiac muscle and germ cells after microwave radiation; 6) Enhancing the activity of GPX of nerves, cardiac muscles and germ cells after microwave irradiation; 7) Enhancing the activity of CAT in nerves, cardiac muscle and germ cells after microwave irradiation; 8) And (3) removing hydroxyl radicals in vitro.
  8. 8. The use according to claim 1, wherein in said use, said shinyleaf yellowhorn kernel extract is administered in advance before microwave irradiation.

Description

Application of shinyleaf yellowhorn extract in preparation of medicines for preventing and/or treating microwave radiation injury Technical Field The invention belongs to the field of medicines, and in particular relates to application of shinyleaf yellowhorn extract in preparation of medicines for preventing and/or treating microwave radiation injury. Background Along with the rapid development of science and technology, the microwave technology is widely applied in a plurality of fields, has deep application in the military and civil fields, provides convenience for people in civil fields such as mobile phone communication, base stations, wireless networks, medical treatment and the like, and causes harm to health by unknowingly exposing people to microwave radiation. In the field of military, the high-intensity complex electromagnetic radiation environment formed by equipment such as radars, electronic countermeasure, microwave weapons and the like can cause different types and degrees of damage to the officers and the soldiers in operation and peripheral operation, and the military operation capability is affected. At present, the microwave radiation is considered to cause damage to a plurality of systems such as nerves, reproduction, heart and the like. The shinyleaf yellowhorn kernel is prepared from seeds of shinyleaf yellowhorn (Xanthocerassorbifolium Bunge) of shinyleaf yellowhorn of Sapindaceae by drying, magnetic separation, shelling, screening and the like. The oil content of the shinyleaf yellowhorn kernel exceeds 60%, the shinyleaf yellowhorn oil is rich in unsaturated fatty acid, and the nervonic acid content is 3% -4%. Clinical application proves that the shinyleaf yellowhorn product has obvious curative effects on enuresis, depression, senile dementia and other neurological diseases. At present, no literature report on the protection of the shinyleaf yellowhorn kernel and the extract thereof in electromagnetic radiation damage is seen. Disclosure of Invention The invention aims to provide medical application of shinyleaf yellowhorn kernel extract. The invention provides medical application of shinyleaf yellowhorn kernel extract, which is application of the shinyleaf yellowhorn kernel extract in preparing medicaments for preventing and/or treating microwave radiation injury. In the application, the shinyleaf yellowhorn kernel extract is residues after oil extraction of shinyleaf yellowhorn kernels. The shinyleaf yellowhorn kernel extract is prepared by a method comprising the following steps: drying shinyleaf yellowhorn kernel, pulverizing, extracting kernel oil by supercritical CO 2, and collecting residue after oil extraction. In the above method, the temperature of supercritical CO 2 extraction may be 35-55deg.C, specifically 35 deg.C, and the extraction pressure may be 15-35MPa, specifically 35MPa; The supercritical CO 2 extraction can be performed a plurality of times, specifically 2 times, each time for 1-2 hours, specifically 2 hours. The above method may further comprise the operation of drying the resulting residue, which may be at a temperature of 40-50 ℃, in particular 40 ℃. The microwave radiation can be specifically S-band microwave radiation with the frequency of 2450MHz. Specifically, the application is the application of the shinyleaf yellowhorn kernel extract in preparing a medicament with any one of the following functions: 1) Improving the survival rate of nerve, cardiac muscle and germ cells after microwave radiation; 2) Reducing apoptosis of nerves, cardiac muscle and germ cells after microwave radiation; 3) Reducing the rise in nerve, myocardium and reproductive ROS caused by microwave radiation; 4) Reducing the rise of nerve, cardiac muscle and reproductive MDA content caused by microwave radiation; 5) Enhancing the activity of SOD of nerve, cardiac muscle and germ cells after microwave radiation; 6) Enhancing the activity of GPX of nerves, cardiac muscles and germ cells after microwave irradiation; 7) Enhancing the activity of CAT in nerves, cardiac muscle and germ cells after microwave irradiation; 8) And (3) removing hydroxyl radicals in vitro. In the application, the shinyleaf yellowhorn kernel extract is administered in advance before microwave radiation. Specifically, 48h ahead of time. In the above application, the medicament contains an effective dose of shinyleaf yellowhorn kernel extract. An effective dose is a unit dosage form (e.g., the amount in a tablet of drug) for administration of a unit dose or a unit dose (e.g., a unit body weight dose) for a treated patient. In the present invention, the subject to be treated with the drug is a human or mammalian species (e.g., rat, etc.). The product of the present invention may be a drug, and the dosage form of the drug is not limited as long as the active ingredient can be effectively formulated into the dosage form in vivo, and includes tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets,